Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients

Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride. mosapride does not block K+ channels or D2 dopaminergic receptors, The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women-, mean age, 67 years) with constipation (10 with bowel movement < 3 times/week-, 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had it worsening. of parkinsonism or other adverse events, Thirteen patients reported subjective improvements ill bowel frequency (3 times/week. 13) and difficult defecation (13). Mosapride Shortened CTT of the left colon (P = 0.01) and the total colon (P = 0.05), During rectal filling. mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude ill rectal contraction (p = 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract niotility. as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients, without serious adverse effects. (c) 2005 Movement Disorder Society